TY - JOUR
T1 - Characteristics associated with inter-individual differences in the trajectories of self-reported attentional function in oncology outpatients receiving chemotherapy
AU - Shih, Juliet
AU - Leutwyler, Heather
AU - Ritchie, Christine
AU - Paul, Steven M.
AU - Levine, Jon D.
AU - Cooper, Bruce
AU - Wright, Fay
AU - Conley, Yvette P.
AU - Miaskowski, Christine
N1 - Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Purpose: Between 14 and 85 % of patients report noticeable changes in cognitive function during chemotherapy (CTX). The purposes of this study were to determine which demographic, clinical, and symptom characteristics were associated with inter-individual variability in initial levels of attentional function as well as with changes in the trajectories of attentional function in a sample of oncology patients who received two cycles of CTX. Methods: Oncology outpatients (n = 1329) were recruited from two comprehensive cancer centers, one veteran’s affairs hospital, and four community-based oncology programs. The Attentional Function Index (AFI) was used to assess perceived effectiveness in completing daily tasks that required working memory and attention. Hierarchical linear modeling (HLM) was used to evaluate for inter-individual variability in initial levels and in the trajectories of attentional function. Results: Demographic, clinical, and symptom characteristics associated with inter-individual differences of attentional function at enrollment (i.e., intercept) were as follows: employment status, functional status, trait anxiety, depressive symptoms, sleep disturbance, evening fatigue, and morning energy. Gender was the only characteristic associated with inter-individual differences in the trajectories of attentional function. Morning fatigue was the only characteristic associated with both initial levels and the trajectories of attentional function. Conclusions: Prior to their next dose of CTX, patients reported moderate levels of attentional function that persisted over two cycles of CTX. Many of the clinical and symptom characteristics associated with decrements in attentional function are amenable to interventions. Clinicians need to assess patients for changes in attentional function and associated characteristics and recommend evidence-based interventions.
AB - Purpose: Between 14 and 85 % of patients report noticeable changes in cognitive function during chemotherapy (CTX). The purposes of this study were to determine which demographic, clinical, and symptom characteristics were associated with inter-individual variability in initial levels of attentional function as well as with changes in the trajectories of attentional function in a sample of oncology patients who received two cycles of CTX. Methods: Oncology outpatients (n = 1329) were recruited from two comprehensive cancer centers, one veteran’s affairs hospital, and four community-based oncology programs. The Attentional Function Index (AFI) was used to assess perceived effectiveness in completing daily tasks that required working memory and attention. Hierarchical linear modeling (HLM) was used to evaluate for inter-individual variability in initial levels and in the trajectories of attentional function. Results: Demographic, clinical, and symptom characteristics associated with inter-individual differences of attentional function at enrollment (i.e., intercept) were as follows: employment status, functional status, trait anxiety, depressive symptoms, sleep disturbance, evening fatigue, and morning energy. Gender was the only characteristic associated with inter-individual differences in the trajectories of attentional function. Morning fatigue was the only characteristic associated with both initial levels and the trajectories of attentional function. Conclusions: Prior to their next dose of CTX, patients reported moderate levels of attentional function that persisted over two cycles of CTX. Many of the clinical and symptom characteristics associated with decrements in attentional function are amenable to interventions. Clinicians need to assess patients for changes in attentional function and associated characteristics and recommend evidence-based interventions.
KW - Attentional function
KW - Chemotherapy
KW - Cognitive function
KW - Executive function
KW - Hierarchical linear modeling
UR - http://www.scopus.com/inward/record.url?scp=84991759948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991759948&partnerID=8YFLogxK
U2 - 10.1007/s00520-016-3461-2
DO - 10.1007/s00520-016-3461-2
M3 - Article
C2 - 27766422
AN - SCOPUS:84991759948
SN - 0941-4355
VL - 25
SP - 783
EP - 793
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 3
ER -